Biomarkers for the Assessment of Congestion in Patients With Ambulatory and Hospitalised Heart Failure
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNHS Greater Glasgow and Clyde
About this trial
The goal of this study is to test the accuracy of new blood and urine tests in people with heart failure. The main question it aims to answer is:
\- Do new blood and urine tests correlate with fluid status? This will be determined by comparison to routine and gold-standard tests in a range of patients with heart failure.
Eligibility criteria
Qualifiers
Written informed consent.
Male or female ≥18 years of age.
Cohort A
Meet European Society of Cardiology (ESC) criteria for diagnosis of HF1, including HF with reduced (HFrEF), mildly reduced (HFmrEF) and preserved ejection fractions (HFpEF).
Disqualifiers
Unwilling to consent.
Unable to consent to inclusion in study due to cognitive impairment.
Previously enrolled in the BIO-CONGEST study.
Current participation in a blinded drug interventional trial (or treatment within four weeks).
Trial design
Treatments tested in this trial
- Urine and circulating blood biomarkers
Treatment groups
140 Participants
are divided into 3 treatment groupsSponsors and collaborators
NHS Greater Glasgow and Clyde
Lead sponsor
University of Glasgow
Collaborator
Roche Diagnostics GmbH
Collaborator
Source ClinicalTrials.gov